Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2025

Revenue Recognition

Schedule of disaggregation of revenues by payer types

	Three months ended				Nine months ended
	September 30,				September 30,
	2025		2024		2025		2024
	(in thousands)
Insurance carriers	$	559,505	$	405,208	$	1,549,140	$	1,130,364
Laboratory partners		25,098		27,622		68,099		70,152
Patients		7,580		6,928		23,376		20,334
Total revenues	$	592,183	$	439,758	$	1,640,615	$	1,220,850

Schedule of total revenue by geographic area

	Three months ended				Nine months ended
	September 30,				September 30,
	2025		2024		2025		2024
	(in thousands)
United States	$	582,371	$	426,274	$	1,612,479	$	1,190,559
Americas, excluding U.S.		1,523		2,002		4,786		5,084
Europe, Middle East, India, Africa		6,006		7,722		17,463		18,339
Asia Pacific and Other		2,283		3,760		5,887		6,868
Total revenues	$	592,183	$	439,758	$	1,640,615	$	1,220,850

Schedule of beginning and ending balances of accounts receivable and deferred revenues

	Balance at
	September 30,		December 31,
	2025		2024
	(in thousands)
Assets:
Accounts receivable, net	$	286,379	$	314,165
Liabilities:
Deferred revenue, current portion	$	21,786	$	19,754
Deferred revenue, long-term portion (1)		16,444		16,838
Total deferred revenues	$	38,230	$	36,592

Schedule of changes in the balance of deferred revenues

	Balance at
	September 30,
	2025			2024
	(in thousands)
Beginning balance	$	36,592	$	35,740
Increase in deferred revenues		30,841		23,968
Revenue recognized during the period included in deferred revenues at the beginning of the period		(16,417)		(12,102)
Revenue recognized from performance obligations satisfied within the same period		(12,786)		(12,804)
Ending balance	$	38,230	$	34,802